CRSP logo

CRSP
CRISPR Therapeutics AG

41,714
Mkt Cap
$5.28B
Volume
15,976.00
52W High
$78.48
52W Low
$30.04
PE Ratio
-9.91
CRSP Fundamentals
Price
$55.30
Prev Close
$53.84
Open
$54.00
50D MA
$55.28
Beta
1.58
Avg. Volume
1.65M
EPS (Annual)
-$4.34
P/B
2.71
Rev/Employee
$94,946.57
News
all
press releases
CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True?
Based on the average brokerage recommendation (ABR), CRISPR Therapeutics (CRSP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Zacks·24h ago
News Placeholder
More News
News Placeholder
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
CRISPR Therapeutics AG (CRSP) closed at $53.84 in the latest trading session, marking a -4.54% move from the prior day.
Zacks·4d ago
News Placeholder
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Hold" from Analysts
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have earned an average recommendation of "Hold" from the twenty-two analysts that are currently covering the stock, Marketbeat.com...
MarketBeat·6d ago
News Placeholder
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 8.7% - Still a Buy?
CRISPR Therapeutics (NASDAQ:CRSP) Trading 8.7% Higher - Time to Buy...
MarketBeat·7d ago
News Placeholder
Three Genomics Stocks Worth Tracking This Year
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
Zacks·7d ago
News Placeholder
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16, representing a +2.58% change from its previous close.
Zacks·8d ago
News Placeholder
Interesting CRSP Put Options For February 20th
Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available this week, for the February 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and...
Nasdaq News: Markets·8d ago
News Placeholder
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry?
Beam Therapeutics advances base-editing pipeline with risto-cel studies and FDA designations, but no approved products and rising competition loom.
Zacks·13d ago
News Placeholder
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.19, moving 1.45% from the previous trading session.
Zacks·14d ago
News Placeholder
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Zacks·14d ago
<
1
2
...
>

Latest CRSP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.